L2: Entry 56 of 83

File: DWPI

Jul 21, 1999

DERWENT-ACC-NO: 1998-207042

DERWENT-WEEK: 199933

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Artificial antigen recognised by anti-filaggrin auto-antibodies - is modified form of filaggrin with citrulline replacing at least one arginine, used for diagnosis of rheumatoid polyarthritis

INVENTOR: ARNAUD, M; DALBON, P; GIRBAL-NEUHAUSER, E; JOLIVET, M; JOLIVET-REYNAUD, C; SEBBAG, M; SERRE, G; SIMON, M; VINCENT, C; GIRBAL NEUHAUSER, E; JOLIVET, R

PATENT-ASSIGNEE:

ASSIGNEE

CODE

BIOMERIEUX SA

INMR

PRIORITY-DATA: 1996FR-0010651 (August 30, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 929669 A1	July 21, 1999	F	000	C12N015/12
WO 9808946 A1	March 5, 1998	F	036	C12N015/12
FR 2752842 A1	March 6, 1998		000	C07K014/78

DESIGNATED-STATES: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE CA US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 929669A1	September 1, 1997	1997EP-0938965	
EP 929669A1	September 1, 1997	1997WO-FR01541	
EP 929669A1		WO 9808946	Based on
WO 9808946A1	September 1, 1997	1997WO-FR01541	
FR 2752842A1	August 30, 1996	1996FR-0010651	

INT-CL (IPC): $\underline{\text{C07}}$ $\underline{\text{K}}$ $\underline{14/47}$; $\underline{\text{C07}}$ $\underline{\text{K}}$ $\underline{14/78}$; $\underline{\text{C12}}$ $\underline{\text{N}}$ $\underline{1/21}$; $\underline{\text{C12}}$ $\underline{\text{N}}$ $\underline{9/78}$; $\underline{\text{C12}}$ $\underline{\text{N}}$ $\underline{15/12}$; $\underline{\text{G01}}$ $\underline{\text{N}}$ $\underline{33/53}$; $\underline{\text{G01}}$ $\underline{\text{N}}$ $\underline{33/542}$; $\underline{\text{G01}}$ $\underline{\text{N}}$ $\underline{33/564}$; $\underline{\text{G01}}$ $\underline{\text{N}}$ $\underline{33/68}$

ABSTRACTED-PUB-NO: WO 9808946A

BASIC-ABSTRACT:

Artificial antigen (Ag) recognised specifically by anti-filaggrin autoantibodies (Ab) present in the serum of patients with rheumatoid polyarthritis (RPA) is a recombinant or synthetic polypeptide containing at least part of a sequence derived from a filaggrin unit, or related molecule, by substitution of at least 1 arginine residue by citrulline (Cit).

 \mbox{USE} - \mbox{Ag} are used for in vitro diagnosis of RPA from complex formation with \mbox{Ab} in usual immunoassays.

ADVANTAGE - Replacement of Arg by Cit is essential for antigen-specific recognition by Ab.

CHOSEN-DRAWING: Dwg.0/5

TITLE-TERMS: ARTIFICIAL ANTIGEN RECOGNISE ANTI AUTO ANTIBODY MODIFIED FORM CITRULLINE REPLACE ONE ARGININE DIAGNOSE RHEUMATISM POLYARTHRITIS

DERWENT-CLASS: BO4 D16 S03

CPI-CODES: B04-B04C2; B04-N02; B12-K04A; D05-H09; D05-H12B2; D05-H17A5;

EPI-CODES: S03-E14H4;

CHEMICAL-CODES:

Chemical Indexing M1 *01* Fragmentation Code M423 M710 M903 P831 Q233 V791



SECONDARY-ACC-NO: CPI Secondary Accession Numbers: C1998-065259 Non-CPI Secondary Accession Numbers: N1998-164439

L5: Entry 6 of 24

File: EPAB

Mar 30, 1999

PUB-NO: US005888833A

DOCUMENT-IDENTIFIER: US 5888833 A

TITLE: Antigens recognized by antibodies to rheumatoid arthritis, their preparation

and their applications

PUBN-DATE: March 30, 1999

INVENTOR-INFORMATION:

NAME SERRE, GUY SOMME, GERARD

VINCENT, CHRISTIAN

COUNTRY

FR FR

ASSIGNEE-INFORMATION:

NAME

COUNTRY

BIOMERIEUX SA

FR

APPL-NO: US25376294 APPL-DATE: June 3, 1994

PRIORITY-DATA: US25376294A (June 3, 1994), FR09104983A (April 26, 1991), FR09111727A (September 24, 1991), FR09200371W (April 24, 1992), US95835393A (January 27, 1993)

INT-CL (IPC): $\underline{\text{CO7}} \times \underline{\text{K}} \times \underline{1/00}$; $\underline{\text{CO7}} \times \underline{\text{K}} \times \underline{14/00}$; $\underline{\text{GO1}} \times \underline{\text{N}} \times \underline{33/564}$; $\underline{\text{GO1}} \times \underline{\text{N}} \times \underline{33/561}$

ABSTRACT:

The present invention relates to antigens extracted from mammalian malpighian epithelia, in particular rat esophageal epithelium or human epidermis, which are specifically recognized by the autoantibodies present in patients suffering form rheumatoid arthritis in respect of antigenic determinants in common with filaggrin and human profilaggrin, as well as to the antigenic proteins of which said antigens are composed and to the peptide fragments derived therefrom. The invention relates to the use of these antigens, proteins and peptide fragments, and that of filaggrin and human profilaggrin, for the preparation of antigenic compositions, and to their applications, in particular for the diagnosis of rheumatoid arthritis. The invention also relates to the preparation of antibodies directed towards these antigens, and to their applications.

L2: Entry 20 of 83

File: DWPI

Dec 12, 2000

DERWENT-ACC-NO: 2001-042649

DERWENT-WEEK: 200115

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Analyzing genetic predisposition to disease, e.g. rheumatoid polyarthritis, by amplification then hybridization to low- and high-resolution oligonucleotide probes

INVENTOR: MOUGIN, B; TIERCY, J M ; TIERCY, J

PATENT-ASSIGNEE:

ASSIGNEE CODE
BIO MERIEUX INMR
BIOMERIEUX SA INMR

PRIORITY-DATA: 1999FR-0006599 (May 20, 1999)

PATENT-FAMILY:

PUB-DATE LANGUAGE PAGES MAIN-IPC PUB-NO 000 C12Q001/68 AU 200047660 A December 12, 2000 061 C120001/68 FR 2793809 A1 November 24, 2000 000 WO 200071750 A1 November 30, 2000 C120001/68

DESIGNATED-STATES: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

APPLICATION-DATA:

PUB-NO APPL

APPL-DATE

APPL-NO

DESCRIPTOR

Based on

AU 200047660A

May 19, 2000

2000AU-0047660

WO 200071750

AU 200047660A FR 2793809A1

December 6, 1999

1999FR-0015314

WO 200071750A1

May 19, 2000 2000WO-FR01385

INT-CL (IPC): C12 Q 1/68

RELATED-ACC-NO: 2001-052292

ABSTRACTED-PUB-NO: FR 2793809A

BASIC-ABSTRACT:

NOVELTY - Analyzing genetic predisposition to at least one disease, comprising treating a liquid sample, containing at least one type of amplicon derived from at least one polymorphic region (PMR) related to the disease, with at least one type-specific probe (P1; low resolution), and at least one subtype-specific probe (P2; high resolution), is new.

DETAILED DESCRIPTION - Analyzing genetic predisposition to at least one disease, comprising treating a liquid sample, containing at least one type of amplicon derived from at least one polymorphic region (PMR) related to the disease, with at least one type-specific probe (P1; low resolution), and at least one subtype-specific probe (P2; high resolution), is new. P1 hybridizes to at least one gene, or a group of alleles of the gene, present in the amplicon and P2 hybridizes to the allele, or group of alleles, specific to P1. P2 can discriminate between one or more alleles associated with susceptibility and/or those alleles associated with resistance to disease, according to whether they hybridize or not.

INDEPENDENT CLAIMS are also included for the following:

- (1) amplification of a sequence corresponding to the group of DRB1 asterisk gr04 alleles using primers (20) and (21);
- (2) amplification of a sequence corresponding to the B27 allele using primers (22), (23) and/or (25) plus (24) and/or (26); and
- (3) combined amplification products of (1) and (2).

 $http://westbrs:8002/bin/gate.exe?f=doc\&...=\&p_Message=\&p_doccnt=1\&p_doc_1=PTFFULL$

CCGGATCCTTCGTGTCCCCACAGCACG (20); TCGCCGCTGCACTGTGAAG (21); GGGAGGAGCGAGGGACCCCAG (22); GGGAGGAGCGAGGGACCGCAG (23); ATCTCGGACCCGGAGACT (24); AGGGGACCGCA (25); and ATCTCGGACCCGGAGACTCG (26). USE - The method is specifically used to detect the HLA alleles associated with susceptibility, or resistance, to rheumatoid polyarthritis, ankylosing spondylitis, disseminated lupus erythematosus, connective tissue disease and Sjogren's syndrome. ADVANTAGE - The process takes less than 2 hours from preparation of the amplicons, to completion, and several genes can be analyzed simultaneously. CHOSEN-DRAWING: Dwg.0/0 TITLE-TERMS: GENETIC DISEASE RHEUMATISM POLYARTHRITIS AMPLIFY LOW HIGH RESOLUTION PROBE DERWENT-CLASS: B04 D16 CPI-CODES: B04-E01; B04-E05; B11-C08E3; B11-C08E5; B12-K04A; B12-K04F; D05-H09; D05-H12D1; D05-H18B; CHEMICAL-CODES: Chemical Indexing M1 *01* Fragmentation Code M423 M720 M750 M781 M905 N102 N134 P831 Q233 Q505 Specfic Compounds AOONSK AOONSA AOONSD AOONSP Chemical Indexing M1 *02* Fragmentation Code M423 M720 M750 M781 M905 N102 N134 P831 Q233 Q505 Specfic Compounds A012PK A012PA A012PD A012PP Chemical Indexing M1 *03* Fragmentation Code M423 M750 M781 M905 N102 N134 P831 Q233 Q505 Specfic Compounds A013IK A013IA A013ID

Chemical Indexing M6 *04* Fragmentation Code M905 P831 Q233 Q505 R502 R511 R515 R521 R627 R639

SECONDARY-ACC-NO: CPI Secondary Accession Numbers: C2001-012435

Print Generate Collection

L2: Entry 43 of 83

File: DWPI

Oct 11, 2000

DERWENT-ACC-NO: 1999-407453

DERWENT-WEEK: 200052

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Peptide containing epitope recognized by anti-filaggrin antibodies, used as immunoassay reagents for diagnosis of rheumatoid polyarthritis

INVENTOR: ARNAUD, M; DALBON, P ; GIRBAL-NEUHAUSER, E ; JOLIVET, M ; JOLIVET-REYNAUD, C ; SEBBAG, M ; SERRE, G ; SIMON, M ; VINCENT, C ; GIRBAL, N E ; JOLIVET, R C ; SERRE, G B R

PATENT-ASSIGNEE:

CODE ASSIGNEE INMR BIO MERIEUX TNMR BIOMERIEUX SA

PRIORITY-DATA: 1997FR-0016673 (December 30, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1042366 A1	October 11, 2000	F	000	C07K014/47
FR 2773157 A1	July 2, 1999		021	C07K014/47
WO 9935167 A1	July 15, 1999	F	000	C07K014/47
AU 9919717 A	July 26, 1999		000	C07K014/47

DESIGNATED-STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 1042366A1	December 29, 1998	1998EP-0964536	
EP 1042366A1	December 29, 1998	1998WO-FR02899	
EP 1042366A1		WO 9935167	Based on
FR 2773157A1	December 30, 1997	1997FR-0016673	
WO 9935167A1	December 29, 1998	1998WO-FR02899	
AU 9919717A	December 29, 1998	1999AU-0019717	
AU 9919717A		WO 9935167	Based on

INT-CL (IPC): A61 K 38/17; C07 K 14/47; G01 N 33/53; G01 N 33/564

ABSTRACTED-PUB-NO: FR 2773157A

BASIC-ABSTRACT:

NOVELTY - Peptide (I) contains an epitope, recognized by anti-filaggrin antibodies (Ab) present in the serum of patients with rheumatoid polyarthritis (RP), comprises a tripeptide motif centered on a citrulline (Cit) residue present in at least one of three peptides of 49, 14 and 14 amino acids (sequences reproduced; fragments of filaggrin).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) artificial antigen (AAg), recognized specifically by Ab, containing, or consisting of, at least one (I);
- (2) antigenic composition for diagnosis of RP containing at least one (I) or AAg, optionally labeled or conjugated to a carrier molecule; and
- (3) kits for detecting Ab containing (I) or AAg, plus suitable buffers and reagents.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - (I) are used as antigen for in vitro detection of Ab, for diagnosis of RP, in standard immunoassays.





 ${\tt ADVANTAGE}$ - ${\tt Ab}$ are markers of RP and their detection makes possible diagnosis at an early stage.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: PEPTIDE CONTAIN EPITOPE ANTI ANTIBODY IMMUNOASSAY REAGENT DIAGNOSE

RHEUMATISM POLYARTHRITIS

DERWENT-CLASS: B04 S03

CPI-CODES: B11-C07A; B12-K04A;

EPI-CODES: S03-E14H4;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M710 M750 M781 M905 N102 P831
Specfic Compounds
A00C8A A00C8N A00C8U

Chemical Indexing M1 *02*
Fragmentation Code
M423 M710 M781 M905 N102 P831 Q505
Specfic Compounds
A00H3D A00H3N A00H3U

Chemical Indexing M6 *03* Fragmentation Code M905 P831 R515 R521 R622 R630

SECONDARY-ACC-NO: CPI Secondary Accession Numbers: C1999-120603 Non-CPI Secondary Accession Numbers: N1999-303959

L2: Entry 43 of 83

File: DWPI

Oct 11, 2000

DERWENT-ACC-NO: 1999-407453

DERWENT-WEEK: 200052

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Peptide containing epitope recognized by anti-filaggrin antibodies, used as immunoassay reagents for diagnosis of rheumatoid polyarthritis

INVENTOR: ARNAUD, M; DALBON, P; GIRBAL-NEUHAUSER, E; JOLIVET, M; JOLIVET-REYNAUD, C; SEBBAG, M; SERRE, G; SIMON, M; VINCENT, C; GIRBAL, N E; JOLIVET, R C; SERRE, G B R

PATENT-ASSIGNEE:

ASSIGNEE CODE
BIO MERIEUX INMR
BIOMERIEUX SA INMR

PRIORITY-DATA: 1997FR-0016673 (December 30, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1042366 A1	October 11, 2000	F	000	C07K014/47
FR 2773157 A1	July 2, 1999 ,		021	C07K014/47
WO 9935167 A1	July 15, 1999	F	000	C07K014/47
AU 9919717 A	July 26, 1999		000	C07K014/47

DESIGNATED-STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

APPLICATION-DATA:

111111111111111111111111111111111111111			
PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 1042366A1	December 29, 1998	1998EP-0964536	
EP 1042366A1	December 29, 1998	1998WO-FR02899	
EP 1042366A1		WO 9935167	Based on
FR 2773157A1	December 30, 1997	1997FR-0016673	
WO 9935167A1	December 29, 1998	1998WO-FR02899	
AU 9919717A	December 29, 1998	1999AU-0019717	
AU 9919717A	•	WO 9935167	Based on

INT-CL (IPC): A61 K 38/17; C07 K 14/47; G01 N 33/53; G01 N 33/564

ABSTRACTED-PUB-NO: FR 2773157A

BASIC-ABSTRACT:

NOVELTY - Peptide (I) contains an epitope, recognized by anti-filaggrin antibodies (Ab) present in the serum of patients with rheumatoid polyarthritis (RP), comprises a tripeptide motif centered on a citrulline (Cit) residue present in at least one of three peptides of 49, 14 and 14 amino acids (sequences reproduced; fragments of filaggrin).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) artificial antigen (AAg), recognized specifically by Ab, containing, or consisting of, at least one (I);
- (2) antigenic composition for diagnosis of RP containing at least one (I) or AAg, optionally labeled or conjugated to a carrier molecule; and
- (3) kits for detecting Ab containing (I) or AAg, plus suitable buffers and reagents.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - (I) are used as antigen for in vitro detection of Ab, for diagnosis of RP, in standard immunoassays.

2/11/02 2:01 PM





 ${\tt ADVANTAGE}$ - ${\tt Ab}$ are markers of RP and their detection makes possible diagnosis at an early stage.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: PEPTIDE CONTAIN EPITOPE ANTI ANTIBODY IMMUNOASSAY REAGENT DIAGNOSE

RHEUMATISM POLYARTHRITIS

DERWENT-CLASS: B04 S03

CPI-CODES: B11-C07A; B12-K04A;

EPI-CODES: S03-E14H4;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M710 M750 M781 M905 N102 P831
Specfic Compounds
A00C8A A00C8N A00C8U

Chemical Indexing M1 *02*
Fragmentation Code
M423 M710 M781 M905 N102 P831 Q505
Specfic Compounds
A00H3D A00H3N A00H3U

Chemical Indexing M6 *03* Fragmentation Code M905 P831 R515 R521 R622 R630

SECONDARY-ACC-NO: CPI Secondary Accession Numbers: C1999-120603 Non-CPI Secondary Accession Numbers: N1999-303959



L5: Entry 15 of 24

File: EPAB

Mar 5, 1998

PUB-NO: WO009808946A1

DOCUMENT-IDENTIFIER: WO 9808946 A1

TITLE: ANTIGENS DERIVED FROM FILAGGRIN AND THEIR USE FOR DIAGNOSING RHEUMATOID

POLYARTHRITIS

PUBN-DATE: March 5, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
SERRE, GUY	FR
GIRBAL-NEUHAUSER, ELISABETH	FR
VINCENT, CHRISTIAN	FR
SIMON, MICHEL	FR
SEBBAG, MIREILLE	FR
DALBON, PASCAL	FR
JOLIVET-REYNAUD, COLETTE	FR
ARNAUD, MICHEL	FR
JOLIVET, MICHEL	FR

ASSIGNEE-INFORMATION:

ASSIGNED INFORMATION.	
NAME	COUNTRY
BIOMERIEUX SA	FR
SERRE GUY	FR
GIRBAL NEUHAUSER ELISABETH	FR ·
VINCENT CHRISTIAN	FR
SIMON MICHEL	FR
SEBBAG MIREILLE	FR
DALBON PASCAL	FR
JOLIVET REYNAUD COLETTE	FR
ARNAUD MICHEL	FR
JOLIVET MICHEL	FR

APPL-NO: FR09701541

APPL-DATE: September 1, 1997

PRIORITY-DATA: FR09610651A (August 30, 1996)

ABSTRACT:

CHG DATE=19980505 STATUS=0>The invention concerns an artificial antigen specifically identified by the anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid polyarthritis, and consisting of one polypeptide comprising all or part of the sequence of one filaggrin unit or of a related molecule, in which an arginine radical has been substituted by a citrulline radical. The invention also concerns the use of this antigen for diagnosing rheumatoid polyarthritis.

2/11/02 1:35 PM

L5: Entry 15 of 24

File: EPAB

Mar 5, 1998

PUB-NO: WO009808946A1

DOCUMENT-IDENTIFIER: WO 9808946 A1

TITLE: ANTIGENS DERIVED FROM FILAGGRIN AND THEIR USE FOR DIAGNOSING RHEUMATOID

POLYARTHRITIS

PUBN-DATE: March 5, 1998

INVENTOR-INFORMATION:

THE BUILDIN THE CHARLES CONT.	
NAME	COUNTRY
SERRE, GUY	FR
GIRBAL-NEUHAUSER, ELISABETH	FR
VINCENT, CHRISTIAN	FR
SIMON, MICHEL	FR
SEBBAG, MIREILLE	FR
DALBON, PASCAL	FR
JOLIVET-REYNAUD, COLETTE	FR
ARNAUD, MICHEL	FR
JOLIVET, MICHEL	FR

ASSIGNEE-INFORMATION:

ADDIGNOO INTOINMITON:	
NAME	COUNTRY
BIOMERIEUX SA	FR
SERRE GUY	FR
GIRBAL NEUHAUSER ELISABETH	FR
VINCENT CHRISTIAN	FR
SIMON MICHEL	FR
SEBBAG MIREILLE	FR
DALBON PASCAL	FR
JOLIVET REYNAUD COLETTE	FR
ARNAUD MICHEL	FR
JOLIVET MICHEL	FR

APPL-NO: FR09701541

APPL-DATE: September 1, 1997

PRIORITY-DATA: FR09610651A (August 30, 1996)

INT-CL (IPC): C12 N 15/12; C12 N 1/21; C07 K 14/47; C12 N 9/78; G01 N 33/53 EUR-CL (EPC): $\overline{\text{C07}}$ K $\overline{\text{014/47}}$

ABSTRACT:

CHG DATE=19980505 STATUS=O>The invention concerns an artificial antigen specifically identified by the anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid polyarthritis, and consisting of one polypeptide comprising all or part of the sequence of one filaggrin unit or of a related molecule, in which an arginine radical has been substituted by a citrulline radical. The invention also concerns the use of this antigen for diagnosing rheumatoid polyarthritis.

2/11/02 1:38 PM

L5: Entry 6 of 24

File: EPAB

Mar 30, 1999

PUB-NO: US005888833A

DOCUMENT-IDENTIFIER: US 5888833 A

TITLE: Antigens recognized by antibodies to rheumatoid arthritis, their preparation

and their applications

PUBN-DATE: March 30, 1999

INVENTOR-INFORMATION:

SERRE, GUY
SOMME, GERARD
VINCENT, CHRISTIAN

COUNTRY FR

FR FR

ASSIGNEE-INFORMATION:

NAME

COUNTRY

BIOMERIEUX SA

FR

APPL-NO: US25376294 APPL-DATE: June 3, 1994

PRIORITY-DATA: US25376294A (June 3, 1994), FR09104983A (April 26, 1991), FR09111727A (September 24, 1991), FR09200371W (April 24, 1992), US95835393A (January 27, 1993)

INT-CL (IPC): $\underline{\text{C07}} \times \underline{\text{I}/00}$; $\underline{\text{C07}} \times \underline{\text{I4/00}}$; $\underline{\text{G01}} \times \underline{\text{N}} \times \underline{33/564}$; $\underline{\text{G01}} \times \underline{\text{N}} \times \underline{33/564}$

ABSTRACT:

The present invention relates to antigens extracted from mammalian malpighian epithelia, in particular rat esophageal epithelium or human epidermis, which are specifically recognized by the autoantibodies present in patients suffering form rheumatoid arthritis in respect of antigenic determinants in common with filaggrin and human profilaggrin, as well as to the antigenic proteins of which said antigens are composed and to the peptide fragments derived therefrom. The invention relates to the use of these antigens, proteins and peptide fragments, and that of filaggrin and human profilaggrin, for the preparation of antigenic compositions, and to their applications, in particular for the diagnosis of rheumatoid arthritis. The invention also relates to the preparation of antibodies directed towards these antigens, and to their applications.